Cinacalcet
Cinacalcet is a medicine that acts as a calcimimetic by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues.Hypercalcemia in parathyroid carcinoma and primary hyperparathyroidism, secondary hyperparathyroidism with chronic kidney disease on dialysis.
Adult : administered orally with food or shortly after a meal. For hypercalcemia in parathyroid carcinoma and primary hyperparathyroidism : start with 30mg twice daily, titrate every 2 to 4 week through subsequent doses of 30, 60 and 90mg twice daily, and 90mg 3 to 4 times daily as required to normalize serum calcium levels. For secondary hyperthyroidism with chronic kidney disease on dialysis: start with 30mg daily, titrate dose every 2 to 4 weeks through subsequent dose of 30, 60, 90, 120 and
Hyopcalcemia.
Monitor intact PTH, serum phosphorus and serum calcium regularly throughout treatment. Monitor patient for signs and syptoms of hypocalcemia. Use with caution in children, pregnancy, lactation, moderate to sever hepatic impairment, impaired cardiac function, adynamic bone disease.
Hypersensitivity reactions. Hypertension, arrhythmia, idiosyncratic hypotension, worsening heart failure. Paresthesia, fatigue, headache, depression, asthenia, dizziness, nausea, vomiting, diarrhea, constipation, dehydration, anorexia, hypercalcemia, fracture, arthralgia, myaligia, limb pain, anemia, upper respiratory infection, noncardiac chest pain.
Drug metabolized by CYP2D6: Plasma concentration of these agents may be elevated. Strong inhibitors of CYP3A4: Cinacalcet concentrations may be elevated. In both cases dosage adjustment may be needed.
